BridgeMD
New treatment option for HIV I Infection
Official title Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
ClinicalTrials.gov ID: NCT06834113
What this study is testing
- What it's testing
- This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®) in patients infected with HIV-1, depending on the injection site and whether or not they are wearing a virtual reality headset.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient aged at least 18 years;
- Patient infected with HIV-1;
- Patient virologically controlled (VL \< 50 copies/ml);
- Patient scheduled to receive treatment with cabotegravir and rilpivirine (naïve patients) or currently on injectable cabotegravir and rilpivirine...
You likely can't join if
- Patient(s) on another injectable antiretroviral treatment;
- Patient participating in another clinical trial with medication;
- Patient(s) with epilepsy;
- Patient on antidepressant treatment;
- Patient(s) with psychiatric or behavioral disorders;
- Patient(s) with a history of dizziness and motion sickness that prevents the use of virtual reality headset;
See the full eligibility criteria
- Patient aged at least 18 years;
- Patient infected with HIV-1;
- Patient virologically controlled (VL \< 50 copies/ml);
- Patient scheduled to receive treatment with cabotegravir and rilpivirine (naïve patients) or currently on injectable cabotegravir and rilpivirine, prescribed by their referring physician.
- Patient(s) on another injectable antiretroviral treatment;
- Patient participating in another clinical trial with medication;
- Patient(s) with epilepsy;
- Patient on antidepressant treatment;
- Patient(s) with psychiatric or behavioral disorders;
- Patient(s) with a history of dizziness and motion sickness that prevents the use of virtual reality headset;
- Patient(s) with visual and hearing impairments that prevent the use of virtual reality headset;
- Patient(s) deprived of liberty, under guardianship or under curatorship;
- Patient(s) not affiliated with a social security scheme;
- Pregnant or breastfeeding women.
The study team makes the final eligibility decision.
Where it's taking place
- Orléans, Loiret, France
- La Roche-sur-Yon, France
- Le Coudray, France
- Nantes, France
- Poitiers, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Orléans, Loiret, France; La Roche-sur-Yon, France; Le Coudray, France; Nantes, France; Poitiers, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.